The historical rank and industry rank for Tonix Pharmaceuticals Holding's OCF Margin % or its related term are showing as below:
TNXP'
s OCF Margin % Range Over the Past 10 Years
Min: -1313.12 Med: -761.76 Max: -603.58
Current: -715.33
During the past 13 years, the highest OCF Margin % of Tonix Pharmaceuticals Holding was -603.58%. The lowest was -1313.12%. And the median was -761.76%.
TNXP's OCF Margin % is ranked worse than 77.27% of 959
companies
in the Biotechnology industry
Industry Median: -66.52
vs TNXP: -715.33
Tonix Pharmaceuticals Holding OCF Margin % Related Terms
Tonix Pharmaceuticals Holding OCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tonix Pharmaceuticals Holding OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Tonix Pharmaceuticals Holding's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tonix Pharmaceuticals Holding (TNXP) has a OCF Margin % of -615.27% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Tonix Pharmaceuticals Holding and its competitors. According to the industry distribution chart, Tonix Pharmaceuticals Holding ranks #741 out of 959 companies in the Biotechnology industry, placing it in the top 77.3%.
Is Tonix Pharmaceuticals Holding's OCF Margin % too high?
Tonix Pharmaceuticals Holding's current OCF Margin % is -615.27%. Based on the distribution chart, Tonix Pharmaceuticals Holding ranks #741 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tonix Pharmaceuticals Holding has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tonix Pharmaceuticals Holding's OCF Margin % compare to UNCY and ENLV?
According to the Biotechnology industry distribution chart, Tonix Pharmaceuticals Holding ranks #741 out of 959 companies for OCF Margin %. This places Tonix Pharmaceuticals Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Tonix Pharmaceuticals Holding and its competitors. Tonix Pharmaceuticals Holding's current OCF Margin % is -615.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonix Pharmaceuticals Holding stock overvalued right now?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding (TNXP) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.75, compared to a current price of $13.11 — trading 649.1% above its estimated fair value. The current OCF Margin % is -615.27%. Tonix Pharmaceuticals Holding's overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Tonix Pharmaceuticals Holding (TNXP), the current OCF Margin % is -615.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tonix Pharmaceuticals Holding (TNXP) Overvalued in 2026?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued.
The current stock price of $13.11 is trading 649.1% above its estimated GF Value™ of $1.75.
GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.
Key valuation signals for TNXP:
OCF Margin %: -615.27%
GF Value™: $1.75 vs. price of $13.11 (649.1% above fair value)
No single metric tells the full story. See the TNXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tonix Pharmaceuticals Holding Business Description
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
41GF Score
Get the complete analysis for TNXP
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNXP has been successfully added to your 
